Abstract: The present invention relates to uses of growth and differentiation factor 8 (GDF-8) in vitro or in vivo for reducing the immunogenicity or risk of rejection of cells such as in particular mesenchymal stem cells (MSC), tissues or materials. The present invention further relates to methods for differentiating MSC in vitro or ex vivo into osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells using FGF-2 and GDF-8. In addition, the present invention relates to osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells obtainable by such methods and to the osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells for use in the treatment of musculoskeletal diseases.

Abstract: The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures, or delayed union fractures.

Abstract: The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits.

Abstract: The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

Abstract: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression.

Abstract: A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Abstract: The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

Abstract: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.